KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Asset Writedowns and Impairment (2016 - 2023)

Historic Asset Writedowns and Impairment for Merck (MRK) over the last 14 years, with Q4 2023 value amounting to $779.0 million.

  • Merck's Asset Writedowns and Impairment fell 715.14% to $779.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $2.8 billion, marking a year-over-year increase of 3841.22%. This contributed to the annual value of $39.0 million for FY2024, which is 9507.58% down from last year.
  • As of Q4 2023, Merck's Asset Writedowns and Impairment stood at $779.0 million, which was down 715.14% from $839.0 million recorded in Q4 2022.
  • In the past 5 years, Merck's Asset Writedowns and Impairment ranged from a high of $1.7 billion in Q4 2020 and a low of $15.0 million during Q3 2020
  • For the 5-year period, Merck's Asset Writedowns and Impairment averaged around $505.9 million, with its median value being $302.0 million (2021).
  • The largest annual percentage gain for Merck's Asset Writedowns and Impairment in the last 5 years was 85625.0% (2020), contrasted with its biggest fall of 9754.9% (2020).
  • Over the past 5 years, Merck's Asset Writedowns and Impairment (Quarter) stood at $176.0 million in 2019, then soared by 856.25% to $1.7 billion in 2020, then crashed by 82.06% to $302.0 million in 2021, then skyrocketed by 177.81% to $839.0 million in 2022, then decreased by 7.15% to $779.0 million in 2023.
  • Its Asset Writedowns and Impairment stands at $779.0 million for Q4 2023, versus $839.0 million for Q4 2022 and $887.0 million for Q3 2022.